PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number: WO 98/46645
С07К 16/00	A2	(43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/EPS (22) International Filing Date: 14 April 1998 (1998) (30) Priority Data: 97106109.8 14 April 1997 (14.04.97) (34) Countries for which the regional or international application was filed: (71)(72) Applicants and Inventors: KUFER, Peter Graf-Konrad-Strasse 2, D-85368 Moosburg (DE). Tobias [DE/DE]; Zentnerstrasse 20, D-80798 (DE). (74) Agent: VOSSIUS & PARTNER; P.O. Box 86 07 67, München (DE).	14.04.9 DE et a [DE/DE, RAUM Münche	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.

(54) Title: NOVEL METHOD FOR THE PRODUCTION OF ANTI-HUMAN ANTIGEN RECEPTORS AND USES THEREOF

(57) Abstract

Described is a method for the production of an anti-human antigen receptor that is low or not immunogenic in humans comprising the steps of selecting a combination of functionally rearranged VH and VL immunoglobulin chains wherein at least said VH chain is derived from essentially unprimed mature human B-lymphocytes or from essentially anergic human B cells and said VL chain is derived from a naturally occurring human B cell repertoire, said chains being expressed from a recombinant vector and using an in vitro display system for binding to a human antigen. Furthermore, receptors that are low or not immunogenic in humans and directed to human antigens are provided, said receptors being obtainable by the method of the invention. Said receptors are preferably antibodies or fragments thereof or immunoconjugates comprising the VH/VL chains of said antibody. In particular, receptors are described directed to human tumor antigens, preferably to the human tumor antigen 17–1A, also known as EpCAM, EGP or GA 733–2. Finally, kits useful for carrying out the method of the invention and pharmaceutical compositions comprising the aforementioned receptors are provided.